ELI LILLY & Co (LLY) Factsheet
Earnings-call transcript: none · IR deck: cataloged — watch a real agent read these end-to-end →
ELI LILLY & Co (LLY) Stock Analysis
Analysis from 10-Q filed 2025-10-30. Data as of Q2 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 44.5%. FCF margin 35.3%. D/E 1.6x. Source: 10-Q filed 2025-10-30.
| Metric | Value | Context |
|---|---|---|
| ROIC | 44.5% | Above industry average |
| FCF Margin | 35.3% | Strong cash generation |
| Debt/Equity | 1.6x | Elevated debt |
ROIC 44.5% — Top 5% of sector peers. FCF margin 35.3% — Top 5%.
Explore ELI LILLY & Co: Earnings History | Filings
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for LLY: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: ELI LILLY & Co earns 44.5% ROIC, Top 5% in Healthcare
ROIC TTM 44.5%, sector median -4.9%, Top 5%. DuPont: NOPAT margin 39.5% × asset turnover 0.7x. Gross margin 83.4%. Operating margin 49.7%. Source: 10-Q filed 2025-10-30.
| Metric | LLY | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 44.5% | Excellent | Above sector median of -4.9% |
| Return on Equity (ROE) | 99.3% | Excellent | Efficient use of shareholder equity |
| Gross Margin | 83.4% | Excellent | Strong pricing power |
| Operating Margin | 49.7% | Excellent | Efficient operations |
Cash Flow: ELI LILLY & Co generates $28.1B FCF at 35.3% margin, positive NaN/8 quarters
FCF TTM $28.1B. FCF margin 35.3%, Top 5%. OCF/Net income 1.1x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-10-30.
| Metric | LLY | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 35.3% | Excellent | Excellent cash conversion |
| Free Cash Flow (TTM) | $28.1B | Good | Positive cash generation |
| OCF/Net Income | 1.1x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: ELI LILLY & Co at 1.6x leverage
Debt/Equity 1.6x. Total debt $54.9B, cash & investments $9.0B. Source: 10-Q filed 2025-10-30.
| Metric | LLY | Rating | Context |
|---|---|---|---|
| Debt to Equity | 1.6x | Warning | Elevated leverage |
| Net Cash Position | $-45.9B | Warning | Net debt position |
Valuation: ELI LILLY & Co trades at 40.2x earnings
P/E 40.2x. EV/Sales 11.6x. FCF yield 2.6%. Dividend yield 0.5%. Source: 10-Q filed 2025-10-30.
| Metric | LLY | Rating | Context |
|---|---|---|---|
| P/E Ratio | 40.2x | Adequate | Premium valuation |
| EV/Sales | 11.6x | Warning | Growth premium priced in |
| FCF Yield | 2.6% | Adequate | Lower cash yield |
| Dividend Yield | 0.5% | Adequate | Growth focus over income |
Capital Allocation: ELI LILLY & Co returns 1.1% shareholder yield
Total shareholder yield 1.1% (div 0.5% + buyback 0.6%). Capital returned $12.0B TTM. Source: 10-Q filed 2025-10-30.
| Metric | LLY | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 1.1% | Adequate | Dividend + buyback yield combined |
| Buyback Yield | 0.6% | Adequate | Minimal buyback activity |
| Total Capital Returned (TTM) | $12.0B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 44.5% | Top 5% | - |
| Free Cash Flow Margin | 35.3% | Top 5% | - |
| Gross Margin | 83.4% | Top 25% | 1.3x above |
| Operating Margin | 49.7% | Top 5% | 40.5x above |
| Return on Equity (ROE) | 99.3% | Top 5% | - |
| P/E Ratio | 40.2x | N/A | - |
Financial Scorecard
| Metric | LLY | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 44.5% | Excellent | Top 5% of sector (median: -4.9%) |
| Free Cash Flow Margin | 35.3% | Excellent | Top 5% of sector (median: 0.0%) |
| Gross Margin | 83.4% | Excellent | Top 25% of sector (median: 64.0%) |
| Debt to Equity Ratio | 162.1% | Warning | High financial leverage |
| P/E Ratio (Price-to-Earnings) | 40.2x | Adequate | High expectations priced in |
| Free Cash Flow Yield | 2.6% | Warning | Growth-focused valuation |
Frequently Asked Questions
Q: What is ELI LILLY & Co's Return on Invested Capital (ROIC)?
ELI LILLY & Co (LLY) has a trailing twelve-month Return on Invested Capital (ROIC) of 44.5%. Sector median -4.9%. Source: 10-Q filed 2025-10-30.
Q: What is ELI LILLY & Co's Free Cash Flow Margin?
ELI LILLY & Co (LLY) has a free cash flow margin of 35.3%, generating $28.1 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-10-30.
Q: What is ELI LILLY & Co's P/E ratio and how does it compare to peers?
ELI LILLY & Co (LLY) trades at a P/E ratio of 40.2x, which is above the sector median of N/A. EV/Sales 11.6x. FCF yield 2.6%. Source: 10-Q filed 2025-10-30.
Q: Does ELI LILLY & Co pay a dividend?
ELI LILLY & Co (LLY) currently pays a dividend yield of 0.5%. Total shareholder yield (dividend + buybacks) 1.1%. Source: 10-Q filed 2025-10-30.
Q: How much debt does ELI LILLY & Co have?
ELI LILLY & Co (LLY) has a debt-to-equity ratio of 1.6x with total debt of $54.9 billion. Net debt $45.9 billion. Source: 10-Q filed 2025-10-30.
Q: What is ELI LILLY & Co's revenue and earnings growth?
ELI LILLY & Co (LLY) grew revenue by 49.6% year-over-year. EPS +94.8% YoY. Source: 10-Q filed 2025-10-30.
Q: Is ELI LILLY & Co buying back stock?
ELI LILLY & Co (LLY) repurchased $6.2 billion of stock over the trailing twelve months. This represents a buyback yield of 0.6%. Source: 10-Q filed 2025-10-30.
Q: How does ELI LILLY & Co compare to competitors in Healthcare?
Compared to other companies in Healthcare, ELI LILLY & Co (LLY) shows: ROIC 44.5%, sector median -4.9% (Top 5%). FCF margin 35.3%, sector median 0.0% (Top 5%). Gross margin 83.4%, 19.4pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with ELI LILLY & Co?
Quantitative warning flags for ELI LILLY & Co (LLY): 1) debt/equity 1.6x (above 1.5x threshold). Source: 10-Q filed 2025-10-30.
Data Source: Data sourced from 10-Q filed 2025-10-30. TTM metrics as of Q2 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.